PMID- 21909041
OWN - NLM
STAT- MEDLINE
DCOM- 20120306
LR  - 20191210
IS  - 1473-5636 (Electronic)
IS  - 0960-8931 (Linking)
VI  - 21
IP  - 6
DP  - 2011 Dec
TI  - Dendritic cell-based vaccine in advanced melanoma: update of clinical outcome.
PG  - 524-9
LID - 10.1097/CMR.0b013e32834b58fa [doi]
AB  - Dendritic cells (DCs) are unique specialized antigen-presenting cells capable of 
      priming naive T cells and inducing antigen-specific cytotoxic T lymphocytes. This 
      study presents an update of clinical results from a DC-based phase I-II clinical 
      vaccine trial in stage IV melanoma. From 2003 to 2010, 27 patients with 
      metastatic melanoma were treated with mature DCs pulsed with autologous tumor 
      lysate and keyhole limpet hemocyanin and with subcutaneous low-dose 
      interleukin-2. Delayed-type hypersensitivity (DTH) tests for in-vivo 
      immunomonitoring were performed at baseline and every four vaccinations 
      thereafter. Two complete, two mixed and six partial responses, and five stable 
      diseases were observed (overall response, 37.0%; clinical benefit, 55.5%). All 15 
      responders showed DTH positivity. A median overall survival of 22.9 months [95% 
      confidence interval (CI): 13.4-61.3] for DTH-positive patients (19) and 4.8 
      months (95% CI: 3.9-11.9) for DTH-negative patients (8; log rank=7.26; P=0.007) 
      was observed. The overall median overall survival was 16 months (95% CI: 9-33). 
      Our results would seem to highlight a relationship between positive-DTH test and 
      an improved survival.
FAU - Ridolfi, Laura
AU  - Ridolfi L
AD  - Immunotherapy Unit, Istituto Scientifico Romagnolo per lo Studio e la Cura dei 
      Tumori, Meldola, Italy.
FAU - Petrini, Massimiliano
AU  - Petrini M
FAU - Fiammenghi, Laura
AU  - Fiammenghi L
FAU - Granato, Anna Maria
AU  - Granato AM
FAU - Ancarani, Valentina
AU  - Ancarani V
FAU - Pancisi, Elena
AU  - Pancisi E
FAU - Brolli, Claudia
AU  - Brolli C
FAU - Selva, Mirna
AU  - Selva M
FAU - Scarpi, Emanuela
AU  - Scarpi E
FAU - Valmorri, Linda
AU  - Valmorri L
FAU - Nicoletti, Stefania Vittoria Luisa
AU  - Nicoletti SV
FAU - Guidoboni, Massimo
AU  - Guidoboni M
FAU - Riccobon, Angela
AU  - Riccobon A
FAU - Ridolfi, Ruggero
AU  - Ridolfi R
LA  - eng
PT  - Evaluation Study
PT  - Journal Article
PL  - England
TA  - Melanoma Res
JT  - Melanoma research
JID - 9109623
RN  - 0 (Cancer Vaccines)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Cancer Vaccines/*therapeutic use
MH  - Clinical Trials, Phase I as Topic
MH  - Clinical Trials, Phase II as Topic
MH  - Dendritic Cells/*immunology
MH  - Disease Progression
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Immunotherapy, Adoptive/*methods
MH  - Male
MH  - Melanoma/diagnosis/mortality/pathology/*therapy
MH  - Middle Aged
MH  - Neoplasm Staging
MH  - Prognosis
MH  - Retrospective Studies
MH  - Skin Neoplasms/diagnosis/mortality/pathology/*therapy
MH  - Survival Analysis
MH  - Treatment Outcome
EDAT- 2011/09/13 06:00
MHDA- 2012/03/07 06:00
CRDT- 2011/09/13 06:00
PHST- 2011/09/13 06:00 [entrez]
PHST- 2011/09/13 06:00 [pubmed]
PHST- 2012/03/07 06:00 [medline]
AID - 10.1097/CMR.0b013e32834b58fa [doi]
PST - ppublish
SO  - Melanoma Res. 2011 Dec;21(6):524-9. doi: 10.1097/CMR.0b013e32834b58fa.